Baker McKenzie advised the German biotechnology company Seamless Therapeutics GmbH on the closing of a $12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key personnel. The carve-out and financing will further the development of Seamless Therapeutics's designer recombinases. The financing round was co-led by life sciences investors Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the life sciences space.
Baker McKenzie advised Seamless Therapeutics on all legal and transactional IP aspects in connection with the financing and in-licensing.
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Its technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. The company is applying its proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Baker McKenzie's Corporate / M&A and life science teams regularly advise big pharma, financial and strategic investors and early-stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised life science investors Andera Partners, Evotec and Fund+ on the successful closing of a EUR 60 million (USD 63 million) Series B financing of Tubulis GmbH, Allecra Therapeutics on an exclusive license and supply agreement with ADVANZ PHARMA, MODAG on a strategic collaboration with Teva, Chord Therapeutics on its sale to Merck KGaA, LSP as lead investor on a EUR 20 million Series A Equity Financing in Innovative Molecules, Numab Therapeutics on a CHF 100 million Cross Over Financing, CatalYm on a EUR 50 million Series B financing led by Vesalius Capital, Casdin Capital on a USD 50 million extension of the Series B Equity Financing in DNA Script, and Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie.
Legal Advisor to Seamless Therapeutics GmbH:
Julia Braun (Corporate/M&A, partner, Munich)
Corporate/M&A: Julia Rossié (associate, Munich), Anna Dzik (associate, Munich)
Employment: Matthias Köhler (partner, Berlin), Harasch Yakubi (associate, Berlin), Kerstin Schmiedel (associate, Berlin)
Transactional IP: Julia Schieber (partner, Zurich), Tiziana Hongler (associate, Zurich)
Antitrust & Competition: Christian Burholt (partner, Berlin)